Core Viewpoint - Casa Minerals Inc. has engaged Independent Trading Group (ITG) for market-making services to enhance liquidity and maintain a reasonable market for its shares, pending regulatory approval [1]. Group 1: Market-Making Agreement - ITG will receive a compensation of CAD$6,000 per month, paid in advance, for an initial term of one month, with automatic renewals unless terminated [2]. - The agreement allows either party to terminate with 30 days' notice and does not include performance factors or compensation in shares or options [2]. Group 2: About Independent Trading Group - ITG is a Toronto-based CIRO dealer-member specializing in market making, liquidity provision, and algorithmic trading solutions, established in 1992 [3]. - The firm utilizes proprietary technology to provide high-quality liquidity and execution services to public issuers and institutional investors [3]. Group 3: About Casa Minerals Inc. - Casa Minerals Inc. focuses on mineral exploration for gold, copper, and strategic minerals in North America, holding a 90% interest in the historic Congress Gold Mine in Arizona [4]. - The company is advancing multiple projects in British Columbia, including the Arsenault copper-gold-silver project, with a commitment to creating shareholder value through the discovery and development of economic mineral deposits [4].

Core Insights - One significant spillover effect of the ongoing conflict is the increase in fertilizer costs [1] Industry Impact - The conflict has led to higher fertilizer prices, which may affect agricultural production and food supply chains [1]

Core Viewpoint - Centessa Pharmaceuticals PLC (NASDAQ:CNTA) shares surged by 44.4% to $39.90 following the announcement of Eli Lilly's acquisition of the company for $6.3 billion, aimed at diversifying its metabolic portfolio with sleep disorder treatments [1] Group 1: Market Reaction - Analysts from Needham and B. Riley downgraded CNTA to "hold" and "neutral," respectively, from "buy," while Piper Sandler also cut its rating to "neutral" from "overweight" [2] - Prior to the acquisition news, 16 out of 17 analysts covering CNTA had "buy" or better ratings, indicating strong bullish sentiment [2] - Options trading activity for CNTA has significantly increased, with 3,467 calls and 2,687 puts traded, which is 11 times the typical volume, highlighting heightened investor interest [2] Group 2: Stock Performance - CNTA is experiencing its best trading day on record, having reached an all-time high of $40.26 [3] - The stock is bouncing off the rising 40-day moving average and has shown a remarkable gain of over 203% over the past nine months [3]

Core Viewpoint - A class action lawsuit has been filed against Pinterest, Inc. and certain officers for alleged violations of federal securities laws during the Class Period from February 7, 2025, to February 12, 2026, seeking damages for affected investors [1]. Company Overview - Pinterest is a visual social media platform where users organize content into "boards" that often include products or services from advertisers [4]. - The platform offers a unique value proposition to advertisers by focusing on users' interests in products and services rather than social connections [5]. - Pinterest generates nearly all of its revenue from advertising, with a significant portion coming from a small number of advertisers, particularly in retail and consumer packaged goods [6]. Allegations and Misstatements - Throughout the Class Period, Pinterest's executives allegedly made materially false and misleading statements regarding the company's business and operations, including overstating its ability to manage the impact of U.S. tariffs on advertising revenues [8]. - The complaint claims that Pinterest was likely to experience reduced revenues from advertising partners and that the company was facing an imminent restructuring due to these issues [8]. Financial Performance and Stock Impact - On November 4, 2025, Pinterest announced Q4 revenue guidance of $1.325 billion, which was below consensus expectations of $1.34 billion, leading to a stock price drop of $7.16 per share (21.76%) [9][10]. - On January 27, 2026, Pinterest revealed a global restructuring plan affecting less than 15% of its workforce, anticipating pre-tax restructuring charges of approximately $35 million to $45 million, resulting in a stock price decline of $2.49 per share (9.61%) [11]. - On February 12, 2026, Pinterest reported quarterly revenue of $1.32 billion, below the consensus estimate of $1.33 billion, and provided Q1 2026 revenue guidance of $951 million to $971 million, also below expectations, causing a further stock price drop of $3.12 per share (16.83%) [12][13].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Inovio Pharmaceuticals, Inc. securities between October 10, 2023, and December 26, 2025, of the April 7, 2026, deadline to become a lead plaintiff in a class action lawsuit [1]. Group 1: Class Action Details - Investors who purchased Inovio securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by April 7, 2026 [3]. - Investors are encouraged to select qualified legal counsel with a successful track record in securities class actions [4]. Group 2: Case Allegations - The lawsuit alleges that defendants made false and misleading statements regarding Inovio's CELLECTRA device manufacturing deficiencies [5]. - It is claimed that Inovio was unlikely to submit the INO-3107 Biologics License Application to the FDA by the second half of 2024 due to insufficient information [5]. - The lawsuit asserts that the overall regulatory and commercial prospects of INO-3107 were overstated, leading to material misstatements by the defendants [5].

Core Viewpoint - A class action lawsuit has been filed against Inovio Pharmaceuticals, Inc. and certain officers for alleged violations of federal securities laws during the Class Period from October 10, 2023, to December 26, 2025, seeking damages for investors who purchased Inovio securities during this time [1] Company Overview - Inovio Pharmaceuticals is a biotechnology company focused on developing DNA medicines to treat diseases, including those associated with human papilloma virus (HPV) [4] - The company's lead product candidate is INO-3107, aimed at treating recurrent respiratory papillomatosis (RRP), a rare disease caused by HPV [5] Product Development and Regulatory Issues - Defendants had previously indicated that they expected the FDA to grant accelerated approval for INO-3107 and aimed to complete the rolling submission of its Biologics License Application (BLA) by the second half of 2024 [5] - However, it was later revealed that manufacturing issues with the CELLECTRA device would delay the BLA submission to mid-2025, representing a full-year delay from the initial timeline [8] Stock Performance and Market Reaction - Following the announcement of the delay in BLA submission on August 8, 2024, Inovio's stock price fell by $0.27 per share, or 3.1%, closing at $8.44 per share [9] - On December 29, 2025, the FDA accepted the INO-3107 BLA on a standard review timeline instead of an accelerated one, leading to a significant drop in stock price by $0.56 per share, or 24.45%, closing at $1.73 per share [10][11] Misleading Statements - Throughout the Class Period, Defendants allegedly made materially false and misleading statements regarding the company's operations and prospects, including deficiencies in manufacturing and overstated regulatory and commercial prospects for INO-3107 [7]

Core Viewpoint - A class action lawsuit has been filed against Picard Medical, Inc. (NYSE: PMI) for alleged fraudulent activities affecting investors who purchased shares between September 2, 2025, and October 31, 2025 [7]. Allegation Details - The lawsuit claims that Picard failed to disclose involvement in a fraudulent stock promotion scheme that utilized social media misinformation and impersonation of financial professionals [7]. - It is alleged that insiders and affiliates used offshore or nominee accounts to facilitate the coordinated dumping of shares during a price inflation campaign [7]. - The company's public statements and risk disclosures reportedly omitted any mention of false rumors and artificial trading activity that influenced the stock price [7]. Stock Performance - On October 24, 2025, Picard's stock price experienced a significant drop of 70%, falling to $3.99 per share [7]. - Following this crash, the share price has continued to decline, reaching approximately $2.00 per share [7]. Legal Process - Investors have until April 3, 2026, to apply to the Court to be appointed as lead plaintiff in the lawsuit [7].

Core Insights - BlackBerry Limited has renewed and expanded its secure communications partnership with the Government of Canada, enhancing the deployment of BlackBerry SecuSUITE for mission-critical communications [1] - The multi-year agreement with Shared Services Canada signifies the Government of Canada's ongoing trust in BlackBerry as a strategic national partner [1] - This partnership emphasizes Canada's commitment to utilizing Canadian-built technology for national security and promoting the global export of trusted sovereign solutions [1] Company Developments - The agreement continues the use of BlackBerry UEM while significantly increasing the deployment of BlackBerry SecuSUITE [1] - The expansion reflects a strategic move to support communications across federal departments and agencies [1] Industry Context - The partnership reinforces the importance of secure communications technology in government operations, particularly in the context of national security [1] - The focus on Canadian-built technology aligns with broader trends in promoting domestic solutions for critical infrastructure [1]

Core Insights - Mercado Pago, the fintech arm of MercadoLibre, is discontinuing its cryptocurrency Mercado Coin, which was launched in 2022 as part of its loyalty program [1][2] - The focus has shifted to "Meli Dolar," a stablecoin pegged to the U.S. dollar, available in Brazil, Mexico, and Chile [2] - Remaining balances of Mercado Coin must be utilized or sold by April 17, or they will be converted to Brazilian reais [3] Group 1 - Mercado Coin was introduced as a cashback incentive for customers in Brazil, the primary market for MercadoLibre [2] - The discontinuation of Mercado Coin is part of a strategic evolution in the company's approach to cryptocurrency [2] - The transition to Meli Dolar indicates a shift towards more stable digital currency offerings [2]

Core Insights - The article emphasizes the value of in-depth analysis in the Biotech sector, highlighting the services offered by Biotech Analysis Central, which includes a model portfolio and extensive research articles [1][2]. Group 1: Company Overview - Biotech Analysis Central provides a subscription service that includes a library of over 600 Biotech investing articles and a model portfolio featuring more than 10 small and mid-cap stocks [2]. - The subscription costs $49 per month, with a discounted annual plan available at $399, representing a 33.50% savings [1]. Group 2: Analyst Background - The author, Terry Chrisomalis, has a background in Applied Science and aims to generate long-term value in the Healthcare sector through his investment insights [2]. - The service is designed to assist Healthcare investors in making informed decisions by providing a range of analysis and news reports [2].